PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay.

08:00 EDT 24th March 2020 | BioPortfolio

Summary of "PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay."

Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway represents a drastic change in the treatment landscape of RCC resulting in a dynamic and evolving scenario. There is an urgent need for predictive biomarkers of response to provide a personalized therapeutic strategy for individual patients.


Journal Details

This article was published in the following journal.

Name: Current drug targets
ISSN: 1873-5592


DeepDyve research library

PubMed Articles [43635 Associated PubMed Articles listed on BioPortfolio]

Selective inhibitors for JNK signalling: a potential targeted therapy in cancer.

c-Jun N-terminal kinase (JNK) signalling regulates both cancer cell apoptosis and survival. Emerging evidence show that JNK promoted tumour progression is involved in various cancers, that include hum...

Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a positive effect on the progression ...

Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.

: As of today, one of the cornerstones of NSCLC treatment is represented by Immune Checkpoint Inhibitors (ICI) treatment in the form of anti PD-1/PD-L1 monoclonal antibodies. However, apart from curre...

Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma.

The incidence of kidney cancer has been increasing steadily and, until recently, there was a substantial lack of effective therapies for a cancer that is now among the 10 most common cancers in men an...

The Jun N-terminal kinases signaling pathway plays a "seesaw" role in ovarian carcinoma: a molecular aspect.

Ovarian cancer is the most common gynecological malignancy that causes cancer-related deaths in women today; this being the case, developing an understanding of ovarian cancer has become one of the ma...

Clinical Trials [22642 Associated Clinical Trials listed on BioPortfolio]

AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation

This is a prospective cohort observational study to assess the role of AlloSure Donor Derived Cell Free DNA (ddcfDNA) assay in the monitoring of three high-risk groups of patients for anti...

Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients

The purpose of this study is to correlate the results of the MICK assay with short- and long-term results of treatments in cancer patients and evaluate the role of the MiCK assay in guidin...

Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal

Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing ear...

Myeloid Derived Suppressor Cells Clinical Assay in Finding and Monitoring Kidney Cancer

This pilot research trial studies the use of the Myeloid Derived Suppressor Cells Clinical Assay in finding and monitoring kidney cancer. Studying samples of blood and urine from patients ...

Biomarkers For Immune Checkpoint Inhibitors

This is a laboratory, non-treatment study. Immune checkpoint inhibitors are a type of immunotherapy that stimulates a patients immune system to fight their cancer. Immune checkpoint inhibi...

Medical and Biotech [MESH] Definitions

In vivo method of screening investigative anticancer drugs and biologic response modifiers for individual cancer patients. Fresh tumor tissue is implanted under the kidney capsule of immunocompetent mice or rats; gross and histological assessments follow several days after tumor treatment in situ.

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.

A complication of kidney diseases characterized by cell death involving KIDNEY PAPILLA in the KIDNEY MEDULLA. Damages to this area may hinder the kidney to concentrate urine resulting in POLYURIA. Sloughed off necrotic tissue may block KIDNEY PELVIS or URETER. Necrosis of multiple renal papillae can lead to KIDNEY FAILURE.

Quick Search

DeepDyve research library

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

An assay is an analytic procedure for qualitatively assessing or quantitatively measuring the presence or amount or the functional activity of a target entity.  This can be a drug or biochemical substance or a cell in an organism or organic sample. ...

Searches Linking to this Article